Skip to main content
Premium Trial:

Request an Annual Quote

Matthew Fust, Swami Swaminathan


Matthew Fust has joined Affymetrix spinoff Perlegen Sciences as the company’s first chief financial officer. Fust served as senior vice president and chief financial officer at drug delivery pioneer Alza, prior to its acquisition by Johnson & Johnson in 200l. Before joining Alza in 1996, Fust was a management consultant at Accenture’s healthcare strategy practice. He received his MBA from Stanford University.

Perlegen CEO Brad Margus said Fust was hired as part of the company’s effort to develop collaborations with the pharmaceutical industry and pursue its own research. Perlegen is using whole wafers of Affymetrix microarrays to compare 50 different human genomes and isolate common patterns of genetic variation.

Millennium Pharmaceuticals’ chief technology officer, Mike Pavia, is leaving the company after five years to become entrepreneur-in-residence at Oxford Bioscience Partners. “It’s time to go out and help incubate the next generation of technologies,” Pavia said in an e-mail to BioArray News’ sister publication GenomeWeb. Pavia will remain a consultant to Millennium.

Microarray software company Strand Genomics of Bangalore, India, has appointed Swami Swaminathan to its scientific advisory board. Swaminathan is senior director of structural chemistry at Gilead and one of the primary authors of the CHARMM software. He is well known for his work in molecular dynamics and is an expert in docking and structural chemistry, the company said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.